- Home
- PLUG vs MYGN Comparison
PLUG vs MYGN Comparison
Compare PLUG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | MYGN |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 625.5M |
| IPO Year | 1999 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PLUG | MYGN |
|---|---|---|
| Price | $2.23 | $6.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $2.11 | ★ $11.82 |
| AVG Volume (30 Days) | ★ 93.3M | 894.7K |
| Earning Date | 11-10-2025 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $676,169,000.00 | ★ $825,300,000.00 |
| Revenue This Year | $13.86 | $0.08 |
| Revenue Next Year | $21.99 | $5.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.53 | 0.21 |
| 52 Week Low | $0.69 | $3.76 |
| 52 Week High | $4.58 | $15.47 |
Technical Indicators
Market Signals| Indicator | PLUG | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 34.44 |
| Support Level | $1.92 | $6.10 |
| Resistance Level | $2.14 | $6.89 |
| Average True Range (ATR) | 0.16 | 0.27 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 56.16 | 3.47 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.